| 1 |
Castellano D, Capdevila J, Sastre J, et al (2013). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish neuroendocrine tumour group (GETNE0801). Eur J Cancer, 49, 3780-7
DOI
|
| 2 |
Delaunoit T, Ducreux M, Boige V, et al (2004). The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer, 40, 515-20.
DOI
|
| 3 |
Desai DC, O'Dorisio TM, Schirmer WJ, et al (2001). Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept, 96, 113-7.
DOI
|
| 4 |
Duran I, Kortmansky J, Singh D, et al (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer, 95, 1148-54.
DOI
|
| 5 |
Eriksson B, Skogseid B, Lundqvist G, et al (1990). Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer, 65, 1883-90.
DOI
|
| 6 |
Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res, 9, 1469-73.
|
| 7 |
Fjallskog ML, Sundin A, Westlin JE, et al (2002). Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol, 19, 35-42.
DOI
|
| 8 |
Fine RL, Gulati AP, Tsushima D, et al (2014). Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol, 32, abstract 179.
|
| 9 |
Raymond E, Dahan L, Raoul JL, et al (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 364, 501-13.
DOI
|
| 10 |
Raymond E, Hobday T, Castellano D, et al (2011). Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev, 30, 19-26.
DOI
|
| 11 |
Rinke A, Muller HH, Schade-Brittinger C, et al (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol, 27, 4656-63.
DOI
|
| 12 |
Schmid HA (2008). Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol, 286, 69-74.
DOI
|
| 13 |
Strosberg JR, Nasir A, Hodul P, Kvols L (2008). Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res, 2, 113-25.
|
| 14 |
Singh S, Dey C, Kennecke H, et al (2014) Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: Guidelines from a Canadian national expert group. Ann Surg Oncol, [Epub ahead of print].
|
| 15 |
Shojamanesh H, Gibril F, Louie A, et al (2002). Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer, 94, 331-43.
DOI
|
| 16 |
Sowa-Staszczak A, Pach D, Stefanska A, et al (2011). Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours? Nucl Med Rev Cent East Eur, 14, 73-8.
DOI
|
| 17 |
Zeng YJ, Liu L, Wu H, et al (2013). Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev, 14, 5775-81.
DOI
ScienceOn
|
| 18 |
Yao JC, Shah MH, Ito T, et al (2011). RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group. everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 364, 514-23.
DOI
|
| 19 |
Yao KA, Talamonti MS, Nemcek A, et al (2001). Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery, 130, 677-82.
DOI
|
| 20 |
Yucel B, Babacan NA, Kacan T, et al (2014). Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pac J Cancer Prev, 14, 6687-92.
|
| 21 |
Zhang J, Francois R, Iyer R, et al (2013). Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst, 105, 1005-17.
DOI
|
| 22 |
Zitzmann K, De Toni EN, Brand S, et al (2007). The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology, 85, 54-60.
DOI
|
| 23 |
Ballian N, Loeffler AG, Rajamanickam V, et al (2009). A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford), 11, 422-8.
DOI
|
| 24 |
Aparicio T, Ducreux M, Baudin E, et al (2001). Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer, 37, 1014-9.
DOI
|
| 25 |
Arnold R, Rinke A, Klose KJ, et al (2005). Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol, 3, 761-71.
DOI
|
| 26 |
Arnold R, Wittenberg M, Rinke A, et al (2013). Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol, 31, abstract 4030.
|
| 27 |
Bajetta E, Catena L, Procopio G, et al (2007). Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol, 59, 637-42.
DOI
|
| 28 |
Baldelli R, Barnabei A, Rizza L, et al (2014). Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne), 5, 7.
|
| 29 |
Chan JA, Stuart K, Earle CC, et al (2012). Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 30, 2963-8.
DOI
|
| 30 |
Chan JA, Blaszkowsky L, Stuart K, et al (2013). A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer, 119, 3212-8
DOI
|
| 31 |
Caplin ME, Pavel M, Cwikla JB, et al (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med, 371, 224-33.
DOI
|
| 32 |
Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008). Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer, 15, 409-27.
DOI
ScienceOn
|
| 33 |
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP (2007). Neuroendocrine tumors. peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab, 21, 111-29.
DOI
|
| 34 |
Gulenchyn KY, Yao X, Asa SL, Singh S, Law C (2012). Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol), 24, 294-308.
DOI
|
| 35 |
Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006). Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a minnie pearl cancer research network Study. J Clin Oncol, 24, 3548-54.
DOI
|
| 36 |
Hirshberg B, Cochran C, Skarulis MC, et al (2005). Malignant insulinoma: spectrum of unusual clinical features. Cancer, 104, 264-72.
DOI
|
| 37 |
Hobday TJ, Qin R, Moore MJ, et al (2013). Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol, 31, abstract 4032.
|
| 38 |
Jensen RT, Berna MJ, Bingham DB, Norton JA (2008). Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer, 113, 1807-43.
DOI
|
| 39 |
Khagi S, Saif MW (2015). Pancreatic neuroendocrine tumors: targeting the molecular basis of disease. Curr Opin Oncol, 27, 38-43.
DOI
|
| 40 |
Kennedy AS, Dezarn WA, McNeillie P, et al (2008). Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol, 31, 271-9.
DOI
|
| 41 |
Kunz PL, Kuo T, Zahn JM, et al (2010). A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol, 28, abstract 4104.
|
| 42 |
Knigge U, Hansen CP, Stadil F (2008). Interventional treatment of neuroendocrine liver metastases. Surgeon, 6, 232-9.
DOI
|
| 43 |
Kouvaraki MA, Ajani JA, Hoff P, et al (2004). Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 22, 4762-71.
DOI
ScienceOn
|
| 44 |
Kulke MH, Hornick JL, Frauenhoffer C, et al (2009). O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res, 15, 338-45.
DOI
|
| 45 |
Kulke MH, Lenz HJ, Meropol NJ, et al (2008). Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 26, 3403-10.
DOI
|
| 46 |
Kulke MH, Stuart K, Enzinger PC, et al (2006). Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol, 24, 401-6.
DOI
|
| 47 |
Kwekkeboom DJ, de Herder WW, Kam BL, et al (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol, 26, 2124-30.
DOI
|
| 48 |
Kvols L, Wiedenmann B, Oberg K, et al (2006). The SOM230 carcinoid study group. safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol, 24, abstract 4082.
|
| 49 |
Missiaglia E, Dalai I, Barbi S, et al (2010). Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol, 28, 245-55.
DOI
|
| 50 |
Mitry E, Baudin E, Ducreux M, et al (1999). Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer, 81, 1351-5.
DOI
ScienceOn
|
| 51 |
Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010). Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther, 31, 169-88.
|
| 52 |
Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med, 326, 519-23.
DOI
|
| 53 |
Niederle MB, Hackl M, Kaserer K, Niederle B (2010). Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer, 17, 909-18.
DOI
ScienceOn
|
| 54 |
Norton JA, Alexander HR, Fraker DL, et al (2003). Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg, 237, 650-7.
|
| 55 |
Oberg K (1992). Interferons in the management of neuroendocrine tumors and their possible mechanism of action. Yale J Biol Med, 65, 519-29.
|
| 56 |
Oberg K (2000). Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion, 62, 92-7.
DOI
|
| 57 |
Oberg K, Casanovas O, Castano JP, et al (2013). Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res, 19, 2842-9.
DOI
|
| 58 |
Pavel M, Baudin E, Couvelard A, et al (2012); Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 95, 157-76.
DOI
|
| 59 |
Olsen IH, Langer SW, Jepsen I, et al (2012). First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol, 51, 97-100.
DOI
|
| 60 |
O'Toole D, Ducreux M, Bommelaer G, et al (2000). Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer, 88, 770-6.
DOI
|
| 61 |
Phan, AT, Yao, JC, Fogelman, DR, et al (2010). A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol, 28, abstract 4001.
|
| 62 |
Panzuto F, Di Fonzo M, Iannicelli E, et al (2006). Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol, 17, 461-6.
DOI
|
| 63 |
Ramage JK, Ahmed A, Ardill J, et al (2012). UK and Ireland neuroendocrine tumour society. guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 61, 6-32.
DOI
|
| 64 |
Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG (2001). Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern cooperative oncology group-E6282. Ann Oncol, 12, 1139-43.
DOI
|
| 65 |
Venook AP, Ko AH, Ko AH, et al (2008). Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol, 26, abstract 216.
|
| 66 |
Strosberg JR, Fine RL, Choi J, et al (2011). First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117, 268-75.
DOI
|
| 67 |
Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005). Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern cooperative oncology group study E1281. J Clin Oncol, 23, 4897-904.
DOI
ScienceOn
|
| 68 |
Tokunaga C, Yoshino K, Yonezawa K (2004). mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun, 313, 443-6.
DOI
|
| 69 |
Villard L, Romer A, Marincek N, et al (2012). Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol, 30, 1100-6.
DOI
|
| 70 |
Yao JC, Phan A, Hoff PM, et al (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26, 1316-23.
DOI
|
| 71 |
Yao JC, Lombard-Bohas C, Baudin E, et al (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol, 28, 69-76.
DOI
|
| 72 |
Yao JC, Hassan M, Phan A, et al (2008). One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26, 3063-72.
DOI
|
webmaster
